Multi-module courses at USD $500, or individual 40-minute modules with quiz at USD $100 each — structured education for healthcare professionals worldwide.
The Institute's flagship programme: twelve modules spanning cannabinoid science, safety, clinical applications and prescribing, taught by international clinicians and researchers.
An evidence-led course on the endocannabinoid system in female physiology and the role of cannabinoid therapeutics across the reproductive lifecycle.
Each module is a 40-minute recorded lecture followed by a quiz, USD $100. Listed alphabetically.
Preclinical and clinical evidence for cannabinoids in brain cancer, and supportive care considerations.
Cannabinoid therapy across multiple sclerosis, movement disorders and other neurological conditions.
Cannabinoids in epilepsy — mechanisms, the trial evidence for CBD and practical clinical considerations.
Anxiety disorders, cannabinoid mechanisms, the current evidence and prescribing cautions.
Mechanisms of chronic and neuropathic pain and an appraisal of the clinical evidence for cannabinoid analgesia.
What medicinal cannabis is, how it is produced and classified, and how it is positioned within contemporary clinical practice.
Absorption, distribution, metabolism and elimination of cannabinoids, drug–drug interactions and the practical safety profile.
Sleep architecture, insomnia and sleep disorders, and what the clinical trial data does and does not show.
The pharmacology, evidence base, dosing considerations and safety profile of CBD in clinical practice.
The endocannabinoid system, metabolic health and the current evidence for medicinal cannabis in diabetes care.
Product selection, formulation choice, titration, monitoring and prescribing frameworks for real patients.
An evidence-led review of inhaled cannabinoid delivery, device considerations and responsible clinical application.
CBG, CBC, CBN and the terpene fraction — pharmacology, emerging evidence and the entourage hypothesis.
Emerging science on the antibacterial and antimicrobial activity of cannabinoids and its clinical relevance.
Receptors, endogenous ligands and metabolic enzymes — how the body's master homeostatic network underpins cannabinoid therapeutics.
